ResearcherShenzhen UniversityActive in the last 2 years
Meng Wang
Matched on ORCID iD 0000-0003-4170-0348; OpenAlex author ID A5100377248. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2022: 3 papers · 2023: none · 2024: none · 2025: 1 paper
Papers 4
- Correction: Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy. Co-author DOI 10.1186/s12951-024-03033-y↗
- Pyroptosis Remodeling Tumor Microenvironment to Enhance Pancreatic Cancer Immunotherapy Driven by Membrane Anchoring Photosensitizer. Co-author DOI 10.1002/advs.202202914↗
- Synergistic interventional photothermal therapy and immunotherapy using an iron oxide nanoplatform for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.actbio.2021.10.048↗
- Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy. Co-author DOI 10.1186/s12951-022-01282-3↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Shiyi Shao · 3 shared papers, 2022–2025 · strength 0.59
- Paper Correction: Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy. DOI 10.1186/s12951-024-03033-y↗
- Paper Pyroptosis Remodeling Tumor Microenvironment to Enhance Pancreatic Cancer Immunotherapy Driven by Membrane Anchoring Ph… DOI 10.1002/advs.202202914↗
- Paper Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy. DOI 10.1186/s12951-022-01282-3↗
- Tingbo Liang · 2 shared papers, 2022–2025 · strength 0.43
- Qida Hu · 2 shared papers, 2022–2025 · strength 0.41
- Xingang Liu · 1 shared paper, 2022 · strength 0.17
- Tingbo Liang · 1 shared paper, 2022 · strength 0.16
- Feifan Zhou · 1 shared paper, 2022 · strength 0.15
- Wei R. Chen · 1 shared paper, 2022 · strength 0.15
- Priyabrata Mukherjee · 1 shared paper, 2022 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.